Soligenix regains oral BDP rights from Sigma-Tau

Soligenix regained the rights to market an oral formulation of beclomethasone dipropionate in Europe and North America after amending a collaboration deal with Sigma-Tau Pharmaceuticals. Beclomethasone dipropionate is a topically active corticosteroid being developed for Crohn's disease in children, gastrointestinal graft-versus-host disease and acute radiation enteritis.

View Full Article in:

Proactive Investors · Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
Washington DC, DC
Director, Corporate Counsel
Tarrytown, NY